Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

A study led by researchers of the Institute of Biomedicine of the University of Barcelona (IBUB) has developed a new ...

Avidity Biosciences, Inc. surges on positive developments in AOCs for muscular disorders, strategic partnerships, and ...

Oral presentation: “Oligonucleotide guided RNA editing of SLC10A1 (NTCP) as a therapeutic approach to lower bile acid re-uptake in cholestatic diseases” Following OTS, the slide deck will be available ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced the company’s launch and $100 million in initial financing, including seed financing and ...

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...

The Food and Drug Administration (FDA) has granted Fast Track designation to zilganersen for the treatment of Alexander disease, a rare type of leukodystrophy.

Avidity Biosciences excels in antibody oligonucleotide conjugates with its stock tripling in the past year due to innovative ...

Venkat Krishnamurthy, Ph.D., Senior Vice President, Head of Platform at Korro, will deliver an oral presentation on KRRO-110, the Company’s first development candidate for the potential treatment of ...